Literature DB >> 17152012

Ferrophilic characteristics of Vibrio vulnificus and potential usefulness of iron chelation therapy.

Choon-Mee Kim1, Ra-Young Park, Mi-Hwa Choi, Hui-Yu Sun, Sung-Heui Shin.   

Abstract

We determined the ferrophilic characteristics of Vibrio vulnificus to evaluate the potential usefulness of iron chelation therapy for the prevention of V. vulnificus infection. Readily available non-transferrin-bound iron (NTBI) is required for the initiation of V. vulnificus growth under in vitro iron-limited conditions and human ex vivo conditions. NTBI aided efficient transferrin-bound iron (TBI) use by V. vulnificus, and the vulnibactin-mediated iron-uptake system was expressed after bacterial growth had been started by NTBI. V. vulnificus required higher NTBI levels for the initiation of growth, produced siderophores at lower levels, and used TBI less efficiently than other bacteria. In addition, the growth of V. vulnificus was inhibited by deferiprone, a clinically available iron chelator. These results show that V. vulnificus is a ferrophilic bacterium that requires higher NTBI levels than other pathogens and that iron chelation therapy might be an effective means of preventing the in vivo growth of V. vulnificus in susceptible patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17152012     DOI: 10.1086/509822

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  12 in total

1.  Cyclic AMP-receptor protein activates aerobactin receptor IutA expression in Vibrio vulnificus.

Authors:  Choon-Mee Kim; Seong-Jung Kim; Sung-Heui Shin
Journal:  J Microbiol       Date:  2012-04-27       Impact factor: 3.422

Review 2.  Vibrio vulnificus: disease and pathogenesis.

Authors:  Melissa K Jones; James D Oliver
Journal:  Infect Immun       Date:  2009-03-02       Impact factor: 3.441

3.  Temperature Change Induces the Expression of vuuA Encoding Vulnibactin Receptor and crp Encoding Cyclic AMP Receptor Protein in Vibrio vulnificus.

Authors:  Choon-Mee Kim; Young-Joon Ahn; Seong-Jung Kim; Dae-Heung Yoon; Sung-Heui Shin
Journal:  Curr Microbiol       Date:  2016-03-25       Impact factor: 2.188

4.  Hepcidin-induced hypoferremia is a critical host defense mechanism against the siderophilic bacterium Vibrio vulnificus.

Authors:  João Arezes; Grace Jung; Victoria Gabayan; Erika Valore; Piotr Ruchala; Paul A Gulig; Tomas Ganz; Elizabeta Nemeth; Yonca Bulut
Journal:  Cell Host Microbe       Date:  2015-01-14       Impact factor: 21.023

5.  In vitro time-kill activities of ciprofloxacin alone and in combination with the iron chelator deferasirox against Vibrio vulnificus.

Authors:  G P Neupane; D-M Kim
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-02-02       Impact factor: 3.267

6.  Iron Loading Exaggerates the Inflammatory Response to the Toll-like Receptor 4 Ligand Lipopolysaccharide by Altering Mitochondrial Homeostasis.

Authors:  Konrad Hoeft; Donald B Bloch; Jan A Graw; Rajeev Malhotra; Fumito Ichinose; Aranya Bagchi
Journal:  Anesthesiology       Date:  2017-07       Impact factor: 7.892

7.  Global gene expression as a function of the iron status of the bacterial cell: influence of differentially expressed genes in the virulence of the human pathogen Vibrio vulnificus.

Authors:  Alejandro F Alice; Hiroaki Naka; Jorge H Crosa
Journal:  Infect Immun       Date:  2008-06-23       Impact factor: 3.441

8.  Role of iron in human serum resistance of the clinical and environmental Vibrio vulnificus genotypes.

Authors:  Ryan W Bogard; James D Oliver
Journal:  Appl Environ Microbiol       Date:  2007-10-12       Impact factor: 4.792

9.  Effect of iron-chelator deferiprone on the in vitro growth of staphylococci.

Authors:  Choon-Mee Kim; Sung-Heui Shin
Journal:  J Korean Med Sci       Date:  2009-04-20       Impact factor: 2.153

10.  In vivo efficacy of the combination of ciprofloxacin and cefotaxime against Vibrio vulnificus sepsis.

Authors:  Hee-Chang Jang; Su-Mi Choi; Hee Kyung Kim; Sung-Eun Kim; Seung-Ji Kang; Kyung-Hwa Park; Phil Youl Ryu; Tae-Hoon Lee; Young Ran Kim; Joon Haeng Rhee; Sook-In Jung; Hyon E Choy
Journal:  PLoS One       Date:  2014-06-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.